Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31252975 | 1.00 | DGKA (0.58) | DGKATSHRCYP3A4ATMTDP1 | |
| SCHEMBL23115475 | 0.97 | DGKA (0.59) | DGKATSHRCYP3A4ATMTDP1 | |
| SCHEMBL23115343 | 0.95 | DGKA (0.61) | DGKATSHRCYP3A4ATMTDP1 | |
| SCHEMBL22465777 | 0.95 | DGKA (0.61) | DGKATSHRCYP3A4ATMTDP1 | |
| SCHEMBL30914742 | 0.95 | DGKA (0.61) | DGKATSHRCYP3A4ATMTDP1 | |
| SCHEMBL22465665 | 0.95 | DGKA (0.61) | DGKATSHRCYP3A4ATMTDP1 | |
| SCHEMBL23115477 | 0.95 | DGKA (0.61) | DGKATSHRCYP3A4ATMTDP1 | |
| SCHEMBL31252970 | 0.94 | TSHR (0.62) | DGKATSHRCYP3A4ATMTDP1 | |
| SCHEMBL23115330 | 0.92 | DGKA (0.57) | DGKATSHRCYP3A4ATMTDP1 | |
| SCHEMBL23115367 | 0.92 | DGKA (0.55) | DGKATSHRCYP3A4ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735417-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | Shanghai Vitalgen Biopharma Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12312293-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250144036-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2025-05-08 | — | — | US | disclosed |
| WO-2025000542-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SHANGHAI VITALGEN BIOPHARMA CO., LTD. (CN) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025002399-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SHANGHAI VITALGEN BIOPHARMA CO., LTD. (CN) | 2025-01-02 | — | — | WO | disclosed |
| EP-4444692-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118369308-A | Compounds and compositions for delivery of therapeutic agents | 摩登纳特斯有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| WO-2022140252-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220106259-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-04-07 | — | — | US | disclosed |
| WO-2021262909-A2 | LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE | MODERNATX, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021262909-A2 | LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE | MODERNATX, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-11066355-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066355-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210087135-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-03-25 | — | — | US | disclosed |
| US-20210087135-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-03-25 | — | — | US | disclosed |
| WO-2021055833-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055833-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144036-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, LNPEP | DGKA 937/4885TSHR 2532/4885CYP3A4 4866/4885 |
| US-12312293-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | PLTP, LNPK, PLIN3 | DGKA 1377/4885TSHR 2764/4885CYP3A4 4877/4885 |
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | MMAB, NSUN3, MSH6 | DGKA 2514/4885TSHR 4464/4885CYP3A4 4793/4885 |
| US-11066355-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | PLTP, LNPK, PLIN3 | DGKA 1377/4885TSHR 2764/4885CYP3A4 4877/4885 |
| US-20210087135-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | DGKA 1377/4885TSHR 2764/4885CYP3A4 4877/4885 |
| US-20220106259-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | DGKA 1377/4885TSHR 2764/4885CYP3A4 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.